PTGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Protagonist Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Protagonist Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was 80.92%. As of today, Protagonist Therapeutics's Piotroski F-Score is 5.
For the Biotechnology subindustry, Protagonist Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Protagonist Therapeutics has the Profitability Rank of 3. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Protagonist Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
Operating Margin % | = | Operating Income (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | 206.309 | / | 254.953 | |
= | 80.92 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Protagonist Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Protagonist Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Protagonist Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Suneel Gupta | officer: Chief Development Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
Patel Dinesh V Ph D | director, officer: President and CEO | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Arturo Md Molina | officer: Chief Medical Officer | 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024 |
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Lewis T Williams | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Bryan Giraudo | director | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
Harold E Selick | director | |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Sarah A O'dowd | director | 3185 LAURELVIEW COURT, FREMONT CA 94538 |
William D. Waddill | director | C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
Asif Ali | officer: Chief Financial Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
Donald A. Kalkofen | officer: Chief Financial Officer | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
David Y Liu | officer: Chief Scientific Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Chaitan Phd Khosla | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Richard S Shame | officer: Chief Medical Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
From GuruFocus
By GuruFocus Research • 01-12-2024
By ACCESSWIRE ACCESSWIRE • 06-06-2023
By ACCESSWIRE • 10-09-2023
By ACCESSWIRE • 01-03-2024
By PRNewswire PRNewswire • 05-12-2023
By ACCESSWIRE • 11-01-2023
By ACCESSWIRE • 08-09-2023
By ACCESSWIRE • 08-17-2023
By ACCESSWIRE • 11-03-2023
By ACCESSWIRE • 10-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.